Biomarker enrichment considerations in oncology early development single-arm studies

Area of Science:

• Oncology
• Biostatistics
• Clinical Trial Design

Background:

• Molecularly targeted agents (MTAs) in oncology show varying effectiveness based on tumor biomarkers.
• Current adaptive Phase III designs focus on confirmatory trials, combining overall and subpopulation efficacy claims.
• Early-phase proof-of-concept (POC) studies need to integrate biomarker analysis for efficient drug development.

Purpose of the Study:

• To propose novel statistical strategies for early-phase single-arm oncology studies.
• To enable detection of efficacy signals in both overall and biomarker-enriched subpopulations.
• To develop methods that maintain statistical rigor without pre-specifying biomarker thresholds.

Main Methods:

• Development of three new statistical methods for single-arm efficacy signal detection.
• Evaluation of proposed methods through simulation studies.
• Focus on addressing biomarker-related questions in early-phase oncology trials.

Main Results:

• The proposed methods allow for claiming statistical significance in either the overall population or a biomarker-enriched subpopulation.
• The strategies maintain statistical rigor despite multiplicity challenges.
• Simulation studies assess the performance of the developed methods.

Conclusions:

• The proposed strategies enhance the efficiency of oncology drug development by integrating biomarker insights early.
• These methods offer a statistically sound approach for identifying potential drug efficacy in specific patient subgroups.
• The findings support the design of early-phase studies that are predictive and enriching for targeted therapies.